Recruiting studies: Immune Effector Cell Associated Neurotoxicity Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence
Phase 4 · 1 location(s) · Centre Hospitalier Universitaire de Saint Etienne · NCT06706102 A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106671 Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07169487 Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
NA · 1 location(s) · University of Utah · NCT07390071 Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome
Phase N/A · 1 location(s) · zhang shoulong · NCT05643092 Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · 6 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT06421675 Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Phase 2 · 17 location(s) · SCRI Development Innovations, LLC · NCT05972135

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.